annual cash & cash equivalents:
$233.00M-$18.10M(-7.21%)Summary
- As of today (May 29, 2025), NBIX annual cash & cash equivalents is $233.00 million, with the most recent change of -$18.10 million (-7.21%) on December 31, 2024.
- During the last 3 years, NBIX annual cash & cash equivalents has fallen by -$107.80 million (-31.63%).
- NBIX annual cash & cash equivalents is now -31.63% below its all-time high of $340.80 million, reached on December 31, 2021.
Performance
NBIX Cash and cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly cash & cash equivalents:
$194.10M-$38.90M(-16.70%)Summary
- As of today (May 29, 2025), NBIX quarterly cash & cash equivalents is $194.10 million, with the most recent change of -$38.90 million (-16.70%) on March 31, 2025.
- Over the past year, NBIX quarterly cash & cash equivalents has dropped by -$202.20 million (-51.02%).
- NBIX quarterly cash & cash equivalents is now -54.36% below its all-time high of $425.30 million, reached on September 30, 2020.
Performance
NBIX quarterly cash & cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and cash equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
NBIX Cash and cash equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -7.2% | -51.0% |
| 3 y3 years | -31.6% | -28.2% |
| 5 y5 years | +107.5% | +3.8% |
NBIX Cash and cash equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -31.6% | at low | -51.0% | +87.0% |
| 5 y | 5-year | -31.6% | +107.5% | -54.4% | +87.0% |
| alltime | all time | -31.6% | +1962.0% | -54.4% | +7751.9% |
NBIX Cash and cash equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2025 | - | $194.10M(-16.7%) |
| Dec 2024 | $233.00M(-7.2%) | $233.00M(-33.3%) |
| Sep 2024 | - | $349.10M(+149.9%) |
| Jun 2024 | - | $139.70M(-64.7%) |
| Mar 2024 | - | $396.30M(+57.8%) |
| Dec 2023 | $251.10M(-4.5%) | $251.10M(-14.5%) |
| Sep 2023 | - | $293.70M(+83.3%) |
| Jun 2023 | - | $160.20M(+54.3%) |
| Mar 2023 | - | $103.80M(-60.5%) |
| Dec 2022 | $262.90M(-22.9%) | $262.90M(+23.9%) |
| Sep 2022 | - | $212.20M(+29.9%) |
| Jun 2022 | - | $163.30M(-39.6%) |
| Mar 2022 | - | $270.20M(-20.7%) |
| Dec 2021 | $340.80M(+82.1%) | $340.80M(+9.5%) |
| Sep 2021 | - | $311.10M(-15.5%) |
| Jun 2021 | - | $368.00M(+4.4%) |
| Mar 2021 | - | $352.60M(+88.5%) |
| Dec 2020 | $187.10M(+66.6%) | $187.10M(-56.0%) |
| Sep 2020 | - | $425.30M(+2.5%) |
| Jun 2020 | - | $415.10M(+122.0%) |
| Mar 2020 | - | $187.00M(+66.5%) |
| Dec 2019 | $112.30M(-20.8%) | $112.30M(-32.6%) |
| Sep 2019 | - | $166.64M(+18.2%) |
| Jun 2019 | - | $140.99M(+93.7%) |
| Mar 2019 | - | $72.78M(-48.6%) |
| Dec 2018 | $141.71M(-44.4%) | $141.71M(-27.6%) |
| Sep 2018 | - | $195.73M(+17.6%) |
| Jun 2018 | - | $166.42M(-5.1%) |
| Mar 2018 | - | $175.31M(-31.2%) |
| Dec 2017 | $254.71M(+205.9%) | $254.71M(-4.9%) |
| Sep 2017 | - | $267.82M(-13.5%) |
| Jun 2017 | - | $309.50M(+382.9%) |
| Mar 2017 | - | $64.09M(-23.0%) |
| Dec 2016 | $83.27M(+12.2%) | $83.27M(-16.5%) |
| Sep 2016 | - | $99.76M(+15.7%) |
| Jun 2016 | - | $86.25M(-25.2%) |
| Mar 2016 | - | $115.30M(+55.4%) |
| Dec 2015 | $74.19M(+139.2%) | $74.19M(+11.8%) |
| Sep 2015 | - | $66.38M(-49.7%) |
| Jun 2015 | - | $132.07M(-22.4%) |
| Mar 2015 | - | $170.26M(+449.0%) |
| Dec 2014 | $31.01M(-30.8%) | $31.01M(+6.8%) |
| Sep 2014 | - | $29.05M(-22.4%) |
| Jun 2014 | - | $37.45M(-64.5%) |
| Mar 2014 | - | $105.53M(+135.6%) |
| Dec 2013 | $44.79M(-29.7%) | $44.79M(+28.4%) |
| Sep 2013 | - | $34.89M(-21.3%) |
| Jun 2013 | - | $44.31M(+40.4%) |
| Mar 2013 | - | $31.55M(-50.5%) |
| Dec 2012 | $63.75M(+27.2%) | $63.75M(+43.3%) |
| Sep 2012 | - | $44.49M(+5.9%) |
| Jun 2012 | - | $42.02M(-45.4%) |
| Mar 2012 | - | $76.94M(+53.6%) |
| Dec 2011 | $50.11M(-7.3%) | $50.11M(+26.8%) |
| Sep 2011 | - | $39.52M(+109.8%) |
| Jun 2011 | - | $18.84M(-22.8%) |
| Mar 2011 | - | $24.39M(-54.9%) |
| Dec 2010 | $54.05M | $54.05M(-30.1%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2010 | - | $77.33M(-18.7%) |
| Jun 2010 | - | $95.12M(+82.1%) |
| Mar 2010 | - | $52.22M(+39.9%) |
| Dec 2009 | $37.33M(-45.5%) | $37.33M(+5.7%) |
| Sep 2009 | - | $35.32M(-8.5%) |
| Jun 2009 | - | $38.62M(-25.3%) |
| Mar 2009 | - | $51.66M(-24.5%) |
| Dec 2008 | $68.47M(-31.3%) | $68.47M(-14.5%) |
| Sep 2008 | - | $80.13M(-12.8%) |
| Jun 2008 | - | $91.92M(-14.6%) |
| Mar 2008 | - | $107.64M(+8.0%) |
| Dec 2007 | $99.66M(+23.1%) | $99.66M(+97.9%) |
| Sep 2007 | - | $50.35M(-2.2%) |
| Jun 2007 | - | $51.48M(-34.4%) |
| Mar 2007 | - | $78.46M(-3.1%) |
| Dec 2006 | $80.98M(+62.1%) | $80.98M(+6.9%) |
| Sep 2006 | - | $75.76M(-12.1%) |
| Jun 2006 | - | $86.17M(-15.1%) |
| Mar 2006 | - | $101.49M(+103.2%) |
| Dec 2005 | $49.95M(-18.2%) | $49.95M(-33.7%) |
| Sep 2005 | - | $75.38M(+55.4%) |
| Jun 2005 | - | $48.50M(+8.8%) |
| Mar 2005 | - | $44.57M(-27.0%) |
| Dec 2004 | $61.03M(-42.3%) | $61.03M(-27.9%) |
| Sep 2004 | - | $84.69M(+272.5%) |
| Jun 2004 | - | $22.73M(-40.2%) |
| Mar 2004 | - | $38.01M(-64.1%) |
| Dec 2003 | $105.85M(+138.9%) | $105.85M(-14.5%) |
| Sep 2003 | - | $123.82M(+254.8%) |
| Jun 2003 | - | $34.90M(-49.0%) |
| Mar 2003 | - | $68.41M(+54.4%) |
| Dec 2002 | $44.31M(-73.0%) | $44.31M(-21.7%) |
| Sep 2002 | - | $56.63M(+18.3%) |
| Jun 2002 | - | $47.86M(-6.7%) |
| Mar 2002 | - | $51.31M(-68.7%) |
| Dec 2001 | $163.89M(+677.5%) | $163.89M(+1271.9%) |
| Sep 2001 | - | $11.95M(-53.0%) |
| Jun 2001 | - | $25.43M(-6.9%) |
| Mar 2001 | - | $27.32M(+29.6%) |
| Dec 2000 | $21.08M(-1.0%) | $21.08M(+88.8%) |
| Sep 2000 | - | $11.16M(+351.6%) |
| Jun 2000 | - | $2.47M(-79.4%) |
| Mar 2000 | - | $11.99M(-43.7%) |
| Dec 1999 | $21.30M(+82.1%) | $21.30M(+180.3%) |
| Sep 1999 | - | $7.60M(-36.1%) |
| Jun 1999 | - | $11.90M(+91.9%) |
| Mar 1999 | - | $6.20M(-47.0%) |
| Dec 1998 | $11.70M(-25.9%) | $11.70M(-37.1%) |
| Sep 1998 | - | $18.60M(+75.5%) |
| Jun 1998 | - | $10.60M(-24.8%) |
| Mar 1998 | - | $14.10M(-10.8%) |
| Dec 1997 | $15.80M(+39.8%) | $15.80M(+4.6%) |
| Sep 1997 | - | $15.10M(-34.1%) |
| Jun 1997 | - | $22.90M(+218.1%) |
| Mar 1997 | - | $7.20M(-36.3%) |
| Dec 1996 | $11.30M | $11.30M(+56.9%) |
| Sep 1996 | - | $7.20M(-66.8%) |
| Jun 1996 | - | $21.70M |
FAQ
- What is Neurocrine Biosciences annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Neurocrine Biosciences?
- What is Neurocrine Biosciences annual cash & cash equivalents year-on-year change?
- What is Neurocrine Biosciences quarterly cash & cash equivalents?
- What is the all time high quarterly cash & cash equivalents for Neurocrine Biosciences?
- What is Neurocrine Biosciences quarterly cash & cash equivalents year-on-year change?
What is Neurocrine Biosciences annual cash & cash equivalents?
The current annual cash & cash equivalents of NBIX is $233.00M
What is the all time high annual cash & cash equivalents for Neurocrine Biosciences?
Neurocrine Biosciences all-time high annual cash & cash equivalents is $340.80M
What is Neurocrine Biosciences annual cash & cash equivalents year-on-year change?
Over the past year, NBIX annual cash & cash equivalents has changed by -$18.10M (-7.21%)
What is Neurocrine Biosciences quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of NBIX is $194.10M
What is the all time high quarterly cash & cash equivalents for Neurocrine Biosciences?
Neurocrine Biosciences all-time high quarterly cash & cash equivalents is $425.30M
What is Neurocrine Biosciences quarterly cash & cash equivalents year-on-year change?
Over the past year, NBIX quarterly cash & cash equivalents has changed by -$202.20M (-51.02%)